Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
Chimeric antigen receptors T cells (CAR T) had been used for treating various tumor patients in clinic, and owned an incredible efficacy in part of malignancies. However, CAR T therapy remains controversial due to doubts about its efficacy and safety in the clinical treatment of various malignancies...
Main Authors: | Wen-Liang Yu, Zi-Chun Hua |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/11/1/47 |
Similar Items
-
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
by: Michael M. Boyiadzis, et al.
Published: (2018-12-01) -
Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
by: Xinrong Xiang, et al.
Published: (2020-12-01) -
Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment
by: Katarzyna M. Terlikowska, et al.
Published: (2021-03-01) -
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
by: Hui Zhou, et al.
Published: (2018-09-01) -
An Estimate of Global Anthrax Prevalence in Livestock: A Meta-analysis
by: Bylaiah Sushma, et al.
Published: (2021-05-01)